COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,889 Articles (22,568 medRxiv, 8,321 bioRxiv)

Most recent first Previous |  Page 1739: Articles 17381-17390  | Next

Comprehensive evaluation of ACE2 expression in female ovary by single-cell RNA-seq analysis
Kong, S., Yan, Z., Yuan, P., Liu, X., Chen, Y., Yang, M., Chen, W., Song, S., Yan, J., Yan, L., Qiao, J.
10.1101/2021.02.23.432460 — Posted: 2021-02-23
Anti-cardiolipin and other anti-phospholipid antibodies in critically ill COVID-19 positive and negative patients
Trahtemberg, U., Rottapel, R., DosSantos, C., Slutsky, A. S., Baker, A. J., Fritzler, M. J.
10.1101/2021.02.19.21252113 — Posted: 2021-02-23
SARS-Cov-2 testing in the United Arab Emirates: Population Attitudes and Beliefs.
Baynouna AlKetbi, L., Nagelkerke, N., Abdelbaqi, H., ALBlooshi, F., AlSaedi, M., Almansoori, S., AlNuaimi, R., AlKhoori, A., AlAryani, A., Al Jiziri, A., AlMestika, N., AlShamsi, M., Kayani, F., Alblooshi, N., AlKhajeh, S., Al Hammadi, I., AlDhahei, S., AlFalahi, J.
10.1101/2021.02.19.21251841 — Posted: 2021-02-23
Structural and functional characterization of SARS-CoV-2 RBD domains produced in mammalian cells
Gstoettner, C., Zhang, T., Resemann, A., Ruben, S., Pengelley, S., Suckau, D., Welsink, T., Wuhrer, M., Dominguez-Vega, E.
10.1101/2021.02.23.432424 — Posted: 2021-02-23
Neutralizing antibody responses 10 months after mild and moderately-severe SARS-CoV-2 infection
Dehgani-Mobaraki, P., Kamber Zaidi, A., Porreca, A., Floridi, A., Floridi, E.
10.1101/2021.02.22.21252225 — Posted: 2021-02-23
Single-Particle Counting Based on Digital Plasmonic Nanobubble Detection for Rapid and Ultrasensitive Diagnostics
Liu, Y., Ye, H., Huynh, H., Kang, P., Xie, C., Kahn, J. S., Qin, Z.
10.1101/2021.02.18.21252027 — Posted: 2021-02-23
Lower respiratory tract sampling via bronchoscopy in COVID-19 ARDS - A focus on microbiology, cellular morphology, cytology and management impact
Bansal, S., Kalpakam, H., Kumar, A., Varshaa, A., Thorbole, A., Mehta, R. M.
10.1101/2021.02.22.21252201 — Posted: 2021-02-23
High-resolution longitudinal serum proteome trajectories in COVID-19 reveal patients-specific seroconversion
Geyer, P. E., Arend, F. M., Doll, S., Louiset, M.-L., Virreira Winter, S., Mueller-Reif, J. B., Torun, F. M., Weigand, M., Eichhorn, P., Bruegel, M., Strauss, M. T., Holdt, L. M., Mann, M., Teupser, D.
10.1101/2021.02.22.21252236 — Posted: 2021-02-23
Critical COVID-19 represents an endothelial disease with high similarity to kidney disease on the molecular level
Siwy, J., Wendt, R., Albalat, A., He, T., Mischak, H., Mullen, W., Latosinska, A., Luebbert, C., Kalbitz, S., Mebazaa, A., Peters, B., Stegmayr, B., Spasovski, G., Wiech, T., Staessen, J., Wolf, J., Beige, J.
10.1101/2021.02.22.21252207 — Posted: 2021-02-23
A cross-sectional study of socioeconomic status and treatment interruption among Japanese workers during the COVID-19 pandemic
Fujimoto, K., Ishimaru, T., Tateishi, S., Nagata, T., Tsuji, M., Eguchi, H., Ogami, A., Matsuda, S., Fujino, Y.
10.1101/2021.02.22.21252190 — Posted: 2021-02-23

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).